Month: May 2020

LAVAL, Québec, May 04, 2020 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, announces it will release its financial results for the first quarter of 2020 after market close on May 12, 2020. Savaria’s management will hold an investor conference call and webcast at 8:30 a.m. Eastern Time (ET) on Wednesday, May 13, 2020. Investors and members of the media are invited to participate on a listen-only basis.Conference call access:Local Dial-in Numbers: (647) 427-7450 or (514) 807-9895North American Toll-Free Number: 1 (888) 231-8191Webcast URL (EN): https://produceredition.webcasts.com/starthere.jsp?ei=1313966&tp_key=bee94a683cAbout Savaria CorporationSavaria Corporation (savaria.com) is one of the global leaders in the accessibility industry. It provides accessibility...

LAVAL, Québec, 04 mai 2020 (GLOBE NEWSWIRE) — Corporation Savaria (« Savaria ») (TSX : SIS) un des chefs de file mondiaux de l’industrie de l’accessibilité, annonce qu’elle divulguera ses résultats financiers pour le premier trimestre 2020 le 12 mai 2020 après la fermeture des marchés. Les membres de la direction de Savaria tiendront une conférence téléphonique et une webdiffusion à l’intention des investisseurs à 8 h 30, heure de l’Est (HE), le mercredi 13 mai 2020. Les investisseurs et les membres des médias sont invités à participer en mode audio seulement.Accès à la conférence téléphonique :Numéros locaux : (647) 427-7450 or (514) 807-9895Numéro sans frais en Amérique du Nord : 1 (888) 231-8191Lien webdiffusion (EN): https://produceredition.webcasts.com/starthere.jsp?ei=1313966&tp_key=bee94a683cÀ propos de Savaria CorporationSavaria...

BARRIE, Ontario, May 04, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that its subsidiary, MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”), has entered into an agreement to supply pharmaceutical-quality (GMP certified), white-label, cannabis oil products to Cannasouth Plant Research New Zealand Limited (“Cannasouth”), a subsidiary of Cannasouth Limited (NZX:CBD). This agreement marks MediPharm Labs Australia’s second white-label supply agreement for the export of finished products to the medical cannabis market in New Zealand.Under the two-year agreement, MediPharm Labs Australia will supply...

CHRISTIANSTED, U.S. Virgin Islands, May 04, 2020 (GLOBE NEWSWIRE) — Front Yard Residential Corporation (“Front Yard” or the “Company”) (NYSE: RESI) announced today that the Company and Amherst Residential, LLC (“Amherst”) have agreed to terminate the previously announced merger agreement pursuant to which Amherst would have acquired Front Yard, and the parties have entered into a settlement agreement with respect to the termination.In connection with the termination of the merger agreement, Amherst has agreed to pay a $25 million fee to Front Yard, purchase 4.4 million shares of Front Yard common stock in a primary issuance at $12.50 per share for an aggregate purchase price of $55 million and provide a $20 million committed two-year unsecured loan facility to Front Yard.“While we are disappointed that the transaction with Amherst...

DALLAS, May 04, 2020 (GLOBE NEWSWIRE) — Dave & Buster’s Entertainment, Inc. (NASDAQ:PLAY) (the “Company”), an owner and operator of entertainment and dining venues, today announced that Jefferies LLC (“Jefferies”) has agreed to purchase $100,000,000 of the Company’s common stock (the “Shares”), to be reoffered by Jefferies at variable prices. In addition, the Company has granted Jefferies an option, exercisable for up to 30 days, to purchase up to an aggregate of an additional $15,000,000 of shares of common stock.The Company currently intends to use the net proceeds from this offering primarily to strengthen its balance sheet, principally as necessitated by the effects of the COVID-19 outbreak on its business, which could include use for general corporate purposes and/or repayment of outstanding debt.This press release is...

SPRINGDALE, Ark., May 04, 2020 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, today reported the following results:1 Adjusted operating income and adjusted net income per share attributable to Tyson, or Adjusted EPS, are non-GAAP financial measures and are explained and reconciled to a comparable GAAP measure at the end of this release.First Six Months HighlightsGAAP EPS of $2.52, down 6% from prior year; Adjusted EPS of $2.43, down 13% from prior yearGAAP operating income of $1,327 million; Adjusted operating income of $1,395 millionTotal Company GAAP operating margin of 6.1% and Adjusted operating margin of 6.4%Record Beef GAAP operating...

NEW YORK and LONDON, May 04, 2020 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will participate and host investor meetings during the STRH Life Sciences Virtual Meeting Series.SunTrust Robinson Humphrey (STRH) Life Sciences Virtual Meetings SeriesDetails: Akari management will participate in a fireside chat and 1-on-1 meetingsFireside chat hosted by STRH biotech analyst Robyn Karnauskas, Ph.D. – Tuesday, May 5, 2020, 11:30 a.m. ET (4:30 BST)Investors interested in arranging a virtual meeting with the Company’s management during this conference should contact the...

— Veteran Industry Executive and Anesthesiologist Brings Significant Clinical and Commercial Experience in Pain Management —PARSIPPANY, N.J., May 04, 2020 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announces the appointment of Donald C. Manning, M.D., Ph.D., as the Company’s Chief Medical Officer, effective immediately. Dr. Manning, who brings more than 20 years of experience in biopharmaceutical executive leadership, was most recently, Chief Medical Officer at Adynxx, Inc., a development company focused on advancing disease-modifying products for the treatment of pain management and inflammation. In his new position, Dr. Manning will report directly to David Stack, chairman and chief executive officer of Pacira BioSciences. “We...

TORONTO, May 04, 2020 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan” or the “Trust”) (TSX: REI.UN) announced today its plans to enhance the shopping experience at its centres across Canada by launching RioCan Curbside Collect™ (“Curbside Collect”), a safe and convenient way for retail tenants and consumers to transact as businesses re-open.Curbside Collect is a new RioCan initiative designed to respond to the evolving retail landscape that offers designated areas for customers to easily access their pre-ordered items from participating stores at applicable RioCan centres in a contactless way. The program is intended to assist businesses to safely ramp back up and serve returning customers as the various levels of government begin to ease restrictions on business closures during the COVID-19 outbreak. Longer term,...

YAVNE, Israel, May 04, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced the expansion of its NexoBrid® European presence with distribution agreements granting GENFA MEDICA SA, its distributer in Russia, Ukraine and the Baltic countries, the exclusive right to market and distribute NexoBrid in France and Switzerland and Specialty Therapeutics PC the exclusive right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus.NexoBrid, currently approved in the European Union and other international markets, is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns. Commercialization of NexoBrid...